Ziresovir Eases Bronchiolitis, Is Safe For Children Two Years And Younger Hospitalized With RSV Infection, Trial Shows

MedPage Today (9/25, Kahn) reports, “An investigational oral antiviral drug eased bronchiolitis and was safe for children 2 years and younger hospitalized with respiratory syncytial virus (RSV) infection, according to a phase III trial in China.” Researchers found that “from baseline to day 3, the RSV F protein inhibitor ziresovir resulted in a 30% greater decrease in the Wang bronchiolitis clinical score compared with placebo.” Study results indicate that “the proportion of children with a reduction of at least 75% on the 0-12 scale at day 3 also favored the ziresovir group.” The findings were published in the New England Journal of Medicine.